Galecto, Inc. (GLTO)

Market Cap	7.65M
Revenue (ttm)	n/a
Net Income (ttm)	-21.17M
Shares Out	1.32M
EPS (ttm)	-19.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,927
Open	6.02
Previous Close	5.90
Day's Range	5.77 - 6.02
52-Week Range	5.62 - 23.50
Beta	1.25
Analysts	Buy
Price Target	10.00 (+72.12%)
Earnings Date	Nov 1, 2024

About GLTO

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2020
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: GLTO
• Website: https://galecto.com

Analyst Forecast

According to one analyst, the rating for GLTO stock is "Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(72.12% upside)

Analyst Consensus: Buy